The US antibody drug conjugates (ADCs) market size is expected to reach around USD 11.29 billion by 2034, growing at a CAGR of 4.11 percent from 2025, according to Nova One Advisor.

The market size is estimated at USD 7.86 billion in 2025, up from USD 7.55 billion in 2024.

This growth is driven by the rising demand for targeted cancer therapies, the increasing prevalence of cancer, innovations in ADC technologies, and a focus on addressing unmet medical needs in oncology.

Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies that combine the accuracy of monoclonal antibodies with the potency of cytotoxic drugs, acting like guided missiles for directly delivering a toxic payload to cancer cells. Advantages of ADCs — including targeted delivery with reduced impact on healthy cells, enhanced potency, and their ability to overcome resistance developed to other treatments — are driving their development and adoption for cancer treatments.

In 2024, the breast cancer segment accounted for the highest market revenue share. However, over the forecast period, the urothelial and bladder cancer segments are anticipated to experience notable growth.

By product, Kadcyla held a major market share in 2024. Moving forward, Enhertu is expected to witness significant growth.

Among targets, the HER2 segment dominated the market in 2024. The CD22 target is projected to register a significant CAGR during the forecast period.

From a technology perspective, cleavable linker technology captured a significant market share in 2024. Meanwhile, the payload technology segment is expected to grow at a notable rate during the forecast period.

According to Nova One Advisor, investment in ADC research and development is increasing, driven by large biopharmaceutical firms, smaller biotech companies, and startups alike, which are focusing on discovering and developing novel and targeted therapies.

Strategic collaborations, mergers and acquisitions, and licensing deals are further propelling market growth.

In June 2025, Simtra BioPharma Solutions formed a strategic alliance with MilliporeSigma to offer comprehensive ADC and bioconjugate manufacturing services. This includes linker and payload production, formulation development, and fill/finish operations.

In June 2025, NextCure, Inc., a clinical-stage biopharmaceutical company, partnered with Simcere Zaiming, an oncology-focused biopharmaceutical company, to develop SIM0505 – a novel ADC designed for targeting CDH6 (cadherin-6 or K-cadherin) to treat solid tumours. 

Regulatory support from the US Food and Drug Administration (FDA)—including breakthrough therapy and orphan drug designations for ADCs — is also encouraging their development. 

Prominent players in the US ADC Market include ADC Therapeutics SA; Astellas Pharma, Inc.; AstraZeneca; Daiichi Sankyo Company Ltd.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Pfizer, Inc.; Seagen, Inc. and Takeda Pharmaceutical Company Ltd.